louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05225155: Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment
Official title: Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Thrombophilia
Fertilization in Vitro
Keywords: female infertility
thrombophilia
enoxaparin
abortion
in vitro fertilization
low molecular weight heparin
Lead sponsor: Faculdade de Medicina do ABC
Sponsor class: OTHER
First posted: 2022-02-04
Enrollment: 104
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All included patients underwent in vitro fertilization (IVF) treatment with intracytoplasmic sperm injection (ICSI). Patients were initially submitted to controlled ovarian hyperstimulation under a short protocol with gonadotropins and GnRH antagonist. Women with laboratorial thrombophilia could be treated or not with enoxaparin according to her physician's decision. Women without detectable thrombophilia formed the control group.

Brief summary: Retrospective study designed to evaluate outcomes in patients undergoing assisted reproduction. Some of them had thrombophilia, and part of them was treated with enoxaparin, started on the day of embryo transfer, and the other part not. Women without thrombophilia formed the control group.

Detailed description: A retrospective study was performed to evaluate the results in 104 patients undergoing to assisted reproduction. Women without thrombophilia were included as controls (n=20), while women with thrombophilia were either treated with 40 mg daily of enoxaparin (treated group, n=54), initiated on the day of embryo transfer, and continued to the week 36 of gestation, or did not receive this medication (untreated group, n= 30).

Eligibility criteria: Inclusion Criteria:

* Women with female infertility or unexplained infertility
* Normal sperm analysis

Exclusion Criteria:

* Women who did not agree with in vitro fertilization techniques

Primary outcomes:
measure: Number of participants with detectable fetal heartbeat
timeFrame: Day 28
measure: Number of participants with detectable ongoing pregnancy
timeFrame: Week 12
measure: Number of participants who delivered a live baby
timeFrame: Week 36
Secondary outcomes:
measure: Number of participants with biochemical gestation detected
timeFrame: Day 14
Other outcomes:
Locations:
city: Santo Andre
country: Brazil
facility: Assistencia Materno Infantil Lambert
state: SP
Study officials:
affiliation: Faculdade de Medicina do ABC
name: Luciano M Pompei
role: STUDY_DIRECTOR
References:
Clinical trial NCT02197455: Tofacitnib for the Treatment of Alopecia Areata and Variants
Official title: Tofacitnib for the Treatment of Alopecia Areata and Variants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alopecia Areata (AA)
Alopecia Totalis (AT)
Alopecia Universalis (AU)
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2014-07-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed description: This study is an open-label pilot study. Participants will be treated with oral tofacitinib for a maximum of 5 months. Participants will be evaluated at 3 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects.

Eligibility criteria: Inclusion Criteria:

* Age \>= 18 years old
* Diagnosis of alopecia areata with \>50% scalp involvement, alopecia totalis, or alopecia universalis
* Hair loss present for at least 6 months
* No treatment for alopecia areata in past 2 months
* No evidence of hair regrowth
* Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication

Exclusion Criteria:

* Age \<18 years old
* Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study
* Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
* Patients known to be HIV or hepatitis B or C positive
* Patients with positive tuberculin skin test or positive QuantiFERON TB test
* Patients with leukopenia or anemia
* Patients with renal or hepatic impairment
* Patients with peptic ulcer disease
* Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors
* Women of childbearing potential who are unable or unwilling to use birth control while taking the medication
* Women who are pregnant or nursing

Primary outcomes:
measure: Mean Change in Severity of Alopecia Tool (SALT) Score
timeFrame: 3 months
Secondary outcomes:
measure: Mean Change in Skindex 16 Scores
timeFrame: 3 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: Brett King, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016 Sep 22;1(15):e89776. doi: 10.1172/jci.insight.89776.
Clinical trial NCT02898155: Potentially Avoidable Hospitalisation in France
Official title: Are Potentially Avoidable Hospitalizations a Good Measure of Access To Primary Care in France?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
COPD
Diabetes
Keywords: Avoidable hospitalizations
primary care
geographicvariation
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2016-09-13
Enrollment: 12000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All patients with at least one hospital admission in the LRMP region in 2014.

Brief summary: Potentially Avoidable Hospitalizations (Pah) Are Studied As An Indirect Measure Of Access To Primary Care And Of The Interface Between Primary And Secondary Care. A Previous Work Unveils Considerable Geographic Variation In The Rate Of Pah In France And Suggest That Primary Care Organization Might Play A Role In This Variation. However, A Limitation Of This Work Lies In The Lack Of Data On Actual Primary Care Utilization.

The Aim Of This Study Is To Analyze The Role Of Primary Care In The Variation Of Potentially Avoidable Hospitalizations At the Zip Code Level, In The French Region Languedoc-Roussillon-Midi-Pyrénées.

The investigator will implement An Ecological Approach In Which The Geographic Variation In The Rate Of Pah Is Analyzed In The French Region Lrmp, Year 2014. Age- And Sex-Adjusted Rate Of Pah By Zip Codes (N=612) Is Modeled Using A Spatial Regression Model.


Eligibility criteria: Inclusion criteria:

* year 2014
* LRMP region
* Hospital admission in any public or private hospital

Exclusion criteria:

* none

Primary outcomes:
measure: Rate of potentially avoidable admissions
timeFrame: 24 months
Secondary outcomes:
measure: Standardized Rate of potentially avoidable admissions
timeFrame: 24 months
Other outcomes:
Locations:
city: Montpellier
country: France
facility: UHMontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Gregoire MERCIER, MD, PhD
role: STUDY_DIRECTOR
affiliation: University Hospital, Montpellier
name: Gregoire mercier, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04014855: Lactoferrin Versus Iron Supplement in Irondeficiency Anemia and Weight Loss in Obese Children
Official title: The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity, Childhood
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-07-10
Enrollment: 50
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effect of lactoferrin versus iron supplement in treating iron deficiency anemia and helping weight loss in obese school age children

Detailed description: Comparing iron versus lactoferrin as regard iron defiency anemia and weight loss in obese children

Eligibility criteria: Inclusion Criteria:

* 1. children age will be between 6 -12 years old. 2. Presence of iron deficiency anemia, it will be diagnosed by

  * CBC \>\> Hemoglobin level concentration below 11.5 g/dl.
  * level of serum iron is below 30 µmol/l,
  * level of ferritin is below 15 µg/dl
  * Total iron binding capacity is more 480 µg/dlL. 3. children should be stable and free from chronic disease. 4. Body Mass index (BMI) should be ≥the 95th percentile for children and teens of the same age and sex.

    5. there is not history of iron supplements in the 3 months before treatment.

Exclusion Criteria:

1. Father/mother refuses to participate in the study.
2. Hospitalized patient.
3. Non-anemic patient.
4. Patients receiving iron supplements 3 months before enrollment.
5. Patients with chronic diseases.
6. personal or family history of allergy to cow's milk or infant formula, eczema, moderate-to-severe allergic rhinitis or asthma, or milk intolerance.
7. severe anemia as Hemoglobin level concentration below 7 g/dl.

Exclusion Criteria:

-

Primary outcomes:
measure: iron deficiency anemia
timeFrame: 3 months
Secondary outcomes:
measure: weight
timeFrame: 3 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Marian Girgis Rizk Abdelsayed
state: Non-US/Non-Canadian
Study officials:
affiliation: Ain Shams University
name: Marian GR Abdelsayed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01072955: Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Prevention of Venous Thromboembolism
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2010-02-22
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective of this study is to verify, through a randomized, blinded, parallel clinical trial, the efficacy of bovine heparin from Eurofarma Laboratory product when compared to porcine heparin APP Pharmaceutical in patients undergoing surgery cardiovascular disease and who require cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on measurements of markers of coagulation ACT, aPTT, anti-Xa heparin levels and the excessive blood loss (hemorrhage) after the end of surgery.


Eligibility criteria: Inclusion Criteria:

* Patients who agree with all aspects of the study and sign the FICT;
* Patients of both sexes;
* Patients over the age of 18 years;
* Patients with indication for cardiac surgery requiring cardiopulmonary bypass.

Exclusion Criteria:

* Patients with hematological disorders that compromise the surgical outcome (eg, myeloproliferative disorders, anemia, Hb \<11.0 g / dL, platelets \<100,000 mm3);
* Patients with disorders of hemostasis (INR\> 1.40) (APTTr\> 1.40);
* Patients with renal impairment (creatinine\> 1.50);
* Patients with deep hyperthermia;
* Liver disease (AST and ALT\> 2 times that of the reference value);
* Patients with a history of allergy to heparin or protamine;
* Patients with a history of heparin-induced thrombocytopenia;
* infection (eg endocarditis, septicemia and pneumonia);
* Reoperations;
* Use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days;
* Use of aspirin for less than 5 days;
* Use of heparin, low molecular weight less than 24 hours;
* Use of unfractionated heparin for less than 12 hours.

Primary outcomes:
measure: Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa
timeFrame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
Secondary outcomes:
measure: Value of the total dose of heparin used, the activity and adequate reversal with the use of protamine.
timeFrame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: LAL Clinica Pesquisa e Desenvolvimento Ltda
state: São Paulo
Study officials:
References:
Clinical trial NCT00689455: Regional Observatory on Metabolic Syndrome- LAZIO
Official title: Regional Observatory on Metabolic Syndrome in Italy- LAZIO
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metabolic Syndrome
Keywords: Metabolic Syndrome
Lipids
Waist Circumference
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-06-03
Enrollment: 1574
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: The aim of the study, is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.


Eligibility criteria: Inclusion Criteria:

* lipid profile in the last year
* Signed informed consent

Exclusion Criteria:

* Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
* Pregnancy or breast feeding
* Subject who are unwilling or unable to provide the informed consent

Primary outcomes:
measure: Prevalence of Metabolic Syndrome in Primary Care Population.
timeFrame: At Visit
Secondary outcomes:
measure: Concomitant presence of other CV risk factors.
timeFrame: At Visit
Other outcomes:
Locations:
city: Rieti
country: Italy
facility: Research Site
city: ROme
country: Italy
facility: Research Site
city: Viterbo
country: Italy
facility: Research Site
Study officials:
affiliation: Cardiology Dept. Director, Sapienza University, Sant' Andrea Hospital, Rome
name: Volpe Massimo, MD, FACC
role: STUDY_CHAIR
References:
Clinical trial NCT01451255: Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
Official title: Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Keywords: pulsatility
normal subjects
mild pulmonary hypertension
exercise-associated pulmonary hypertension
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2011-10-13
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population will consist of a total of 90 subjects separated evenly into the following subgroups: 1) Mild PAH, 2) Moderate or Severe PAH, and 3) Normal Controls.

Brief summary: Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness. In addition, cardiac MRI could play provide early and effective treatment for Pulmonary Arterial Hypertension (PAH).


Eligibility criteria: Inclusion Criteria:

Consecutive patients aged ≥ 18 years with PAH as dictated by a comprehensive examination and echocardiography will be included for enrollment.

Exclusion Criteria:

* Age \< 18 years
* Pregnancy
* Mechanical ventilation
* Acute or chronic renal failure (creatinine clearance \< 30 ml/min or requiring renal replacement therapy)
* Inability to perform MRI (i.e. claustrophobia, severe obesity (\> 150 kg), device incompatible with MRI)
* Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths)
* Prior heart or lung transplantation
* Left ventricular systolic (ejection fraction \< 50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction)
* Significant left-sided valvular disease (≥ moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Brian Shapiro, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ray JC, Burger C, Mergo P, Safford R, Blackshear J, Austin C, Fairweather D, Heckman MG, Zeiger T, Dubin M, Shapiro B. Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. Int J Cardiovasc Imaging. 2019 Oct;35(10):1881-1892. doi: 10.1007/s10554-018-1397-y. Epub 2018 Jun 22.
Clinical trial NCT06950814: Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Official title: Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sarcomatoid Carcinoma
Liver Cancer
Adjuvant Therapy
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.

Brief summary: In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.


Eligibility criteria: Inclusion Criteria:

1. patients who underwent liver resection
2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion Criteria:

1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
2. patients diagnosed with other specific types of sarcomas;
3. patients with concurrent other malignancies during the course of PHSC;
4. patients who were lost to follow-up or lacked essential clinical data.

Primary outcomes:
measure: Disease-free survival
timeFrame: From December 2018 to May 2023
Secondary outcomes:
measure: Overall survival
timeFrame: From December 2018 to May 2023
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital
state: Sichuan
Study officials:
References:
Clinical trial NCT00051714: Early Prevention of Conduct Problems
Official title: Early Primary Prevention of Conduct Problems
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Conduct Disorder
Keywords: Social Behavior Disorders
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2003-06-04
Enrollment: 1050
Sex: ALL
Minimum age (years): 33
Maximum age (years): 63
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine the immediate and long-term effects of a prevention program in children at risk for developing conduct problems and antisocial behavior.

Detailed description: Participants are randomly assigned to a year-long family-based intervention or to a no contact control group. The intervention focuses on improving parenting practices, parent-child interactions, and child social competence.

Children are assessed at the beginning of the study and again after one year. The development of conduct problems, social competence, and school functioning is assessed from second through fifth grade. Assessments are made through observations, parent and teacher ratings, and diagnostic interviews.

Eligibility criteria: Inclusion Criteria:

* Sibling of youth adjudicated in Family Court

Primary outcomes:
measure: behavior problems
timeFrame: March 1997 - December 2012
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University Child Study Center
state: New York
Study officials:
References: